Clopidogrel Versus Newer P2Y12 Antagonists for Percutaneous Coronary Intervention in Patients with Out-of-Hospital Cardiac Arrest Managed with Therapeutic Hypothermia: A Meta-Analysis by Elbadawi, Ayman et al.
University of Kentucky
UKnowledge
Internal Medicine Faculty Publications Internal Medicine
12-2018
Clopidogrel Versus Newer P2Y12 Antagonists for
Percutaneous Coronary Intervention in Patients
with Out-of-Hospital Cardiac Arrest Managed with
Therapeutic Hypothermia: A Meta-Analysis
Ayman Elbadawi









See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
Part of the Cardiology Commons
This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine
Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Elbadawi, Ayman; Elgendy, Islam Y.; Mohamed, Ahmed H.; Barssoum, Kirolos; Alotaki, Erfan; Ogunbayo, Gbolahan O.; and Ziada,
Khaled M., "Clopidogrel Versus Newer P2Y12 Antagonists for Percutaneous Coronary Intervention in Patients with Out-of-Hospital
Cardiac Arrest Managed with Therapeutic Hypothermia: A Meta-Analysis" (2018). Internal Medicine Faculty Publications. 162.
https://uknowledge.uky.edu/internalmedicine_facpub/162
Authors
Ayman Elbadawi, Islam Y. Elgendy, Ahmed H. Mohamed, Kirolos Barssoum, Erfan Alotaki, Gbolahan O.
Ogunbayo, and Khaled M. Ziada
Clopidogrel Versus Newer P2Y12 Antagonists for Percutaneous Coronary Intervention in Patients with Out-of-
Hospital Cardiac Arrest Managed with Therapeutic Hypothermia: A Meta-Analysis
Notes/Citation Information
Published in Cardiology and Therapy, v. 7, issue 2, p. 185-189.
© The Author(s) 2018
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes
were made.
Digital Object Identifier (DOI)
https://doi.org/10.1007/s40119-018-0118-x
This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/162
BRIEF REPORT
Clopidogrel Versus Newer P2Y12 Antagonists
for Percutaneous Coronary Intervention in Patients
with Out-of-Hospital Cardiac Arrest Managed
with Therapeutic Hypothermia: A Meta-Analysis
Ayman Elbadawi . Islam Y. Elgendy . Ahmed H. Mohamed .
Kirolos Barssoum . Erfan Alotaki . Gbolahan O. Ogunbayo .
Khaled M. Ziada
Received: July 17, 2018 / Published online: September 4, 2018
 The Author(s) 2018
ABSTRACT
Introduction: The impact of therapeutic
hypothermia (TH) on outcomes of percuta-
neous coronary intervention (PCI) and the
optimal antiplatelet treatment remains
debatable.
Methods: Electronic databases were searched
for randomized trials and observational studies
to evaluate the available clinical evidence
comparing the use of clopidogrel versus newer
P2Y12 antagonists in cases of TH after PCI. The
primary outcome was in-hospital definite stent
thrombosis while the secondary outcomes were
in-hospital mortality and major bleeding. Fixed-
effects risk ratios (RRs) were estimated using
Mantel–Haenszel method.
Results: The final analysis included five studies
with a total of 290 patients. There was no dif-
ference in the incidence of stent thrombosis (RR
0.92; 95% CI 0.35–2.38), in-hospital mortality
(RR 1.38; 95% CI 0.72–2.65), and major bleed-
ing (RR 0.89; 95% CI 0.33–2.40) between
patients receiving clopidogrel versus those
receiving newer agents.
Conclusions: This meta-analysis showed no
difference between clopidogrel and newer anti-
platelet agents in the incidence of stent
thrombosis or in-hospital mortality for PCI in
cases of TH. Further randomized studies are
needed to explore the optimal dual antiplatelet
treatment in TH.
Keywords: Anti-platelets; Percutaneous
coronary intervention; Stent thrombosis;
Therapeutic hypothermia
INTRODUCTION
Out of hospital cardiac arrest (OHCA) carries a
significant mortality worldwide [1]. Therapeutic
hypothermia (TH) as well as early percutaneous
coronary intervention (PCI) for patients with
OHCA and suspected myocardial injury have
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been shown to improve outcomes [2, 3]. The
impact of TH on outcomes of PCI remains
debatable. Some studies have demonstrated
higher incidence of stent thrombosis associat-
ing TH after PCI [3, 4]. Experimental studies
have raised concerns regarding the efficacy of
clopidogrel in cases of hypothermia, possibly by
augmenting adenosine diphosphate (ADP)-
induced platelet aggregation [5]. Hypothermia
also impairs the pharmacokinetic profile of
clopidogrel including its absorption, and enzy-
matic activation to the active metabolites [1, 5].
Some studies showed a better platelet inhibition
with ticagrelor and prasugrel compared to
clopidogrel in TH [2, 6]. However, the clinical
translation of these experimental observations
is not clear. We conducted this meta-analysis to
evaluate the available clinical evidence com-
paring the use of clopidogrel versus newer
P2Y12 antagonists in cases of TH after PCI.
METHODS
We performed a computerized search of MED-
LINE, EMBASE, and COCHRANE databases
through December 2017, for studies on sur-
vivors of OHCA receiving TH who underwent
PCI. A similar search strategy was also done for
abstracts of the major scientific sessions
(American College of Cardiology, European
Society of Cardiology, the American Heart
Association and European Association of Car-
diothoracic Anesthesiologists) up to December
2017. We further screened the bibliographies of
the retrieved studies as well as clinicaltrials.gov
for any relevant studies not retrieved by the
initial search. Studies were included when
clinical outcomes for patients receiving clopi-
dogrel versus one of the newer antiplatelet
agents (ticagrelor or prasugrel) were reported.
The study designs, intervention strategies and
main outcomes were extracted by two investi-
gators (A.H and K.B). Discrepancies among
investigators were resolved by consensus. The
primary outcome was in-hospital definite stent
thrombosis. Identified cases of definite stent
thrombosis were established in all studies in
accordance with the Academic Research Con-
sortium definition [7]. Secondary outcomes
included in-hospital mortality and major
bleeding. Fixed-effects and random-effects risk
ratios (RRs) were estimated using Man-
tel–Haenszel method. Heterogeneity was calcu-
lated using the I2 test. Statistical analyses were
conducted using RevMan 5.0 software
(Cochrane Collaboration, Oxford, UK). The
current analysis was conducted in accordance
with the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) Check-
list (Supplemental Table 1). We used the New-
castle–Ottawa score to assess the quality of
included studies [8].
This article does not contain any studies
with human participants or animals performed
by any of the authors.
RESULTS
Our final analysis included five studies with a
total of 290 patients. One study was a prospec-
tive randomized-controlled trial [2], while two
studies were prospective non-randomized [1, 6]
and two studies were retrospective studies [3, 4].
In those studies, TH protocols included main-
taining a temperature of 32–34 C for 12–24 h
(Table 1). In all studies, patients received peri-
procedural aspirin and P2Y12 receptor inhibi-
tors via nasogastric tube. Baseline characteristics
Fig. 1 Forrest plot for definite stent thrombosis for clopidogrel versus newer anti-platelet agents. ST stent thrombosis
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of included studies are described in Supple-
mental Table 2. Using Newcastle–Ottawa score
all studies were assessed to have good quality,
except one study of fair quality [2] (Supple-
mental Table 3). The incidence of stent throm-
bosis was not different between patients
receiving clopidogrel 9 (6.1%) versus those
receiving newer agents 9 (6.3%) (RR 0.92; 95%
CI 0.35–2.38; p = 0.86) with moderate hetero-
geneity (I2 = 45%) (Fig. 1). Sub-group analysis
showed no difference between clopidogrel ver-
sus newer agents in retrospective studies (RR
0.92; 95% CI 0.31–2.71; p = 0.88) compared
with prospective studies (RR 0.91; 95% CI
0.12–6.91; p = 0.93) (Pinteraction = 0.99). Further
sub-group analysis showed no difference when
comparing clopidogrel versus ticagrelor (RR
1.09; 95% CI 0.37–3.24; p = 0.88) or clopidogrel
versus prasugrel (RR 0.38; 95% CI 0.09–1.51;
p = 0.17) (Pinteraction = 0.24). In-hospital all-
cause mortality (reported in three studies) was
not statistically different between clopidogrel
20 (24.4%) and newer agents 11 (15.5%) (RR
1.38; 95% CI 0.72–2.65; p = 0.34; I2 = 0%)
[1, 4, 6]. Similarly, three studies reported major
bleeding events [1, 4, 6], and no significant
difference was detected between clopidogrel 8
(9.8%) and newer agents 7 (9.9%) (RR 0.89; 95%
CI 0.33–2.40; p = 0.82; I2 = 0%). Publication
bias could not be assessed due to the few num-
ber of studies included in the analysis.
DISCUSSION
This meta-analysis of five clinical studies with a
total of 290 patients demonstrated that among
patients receiving TH after PCI, no significant
difference existed between clopidogrel and
newer agents (ticagrelor or prasugrel) regarding
in-hospital stent thrombosis, all-cause mortality
or major bleeding. Overall, the incidences of
stent thrombosis in our analysis (6.1% with
clopidogrel and 6.3% with newer agents) was
higher than reported incidences of stent
thrombosis in non-hypothermia conditions [9].
Little evidence is available regarding the
optimal dual antiplatelet regimen in OHCA
patients receiving TH after PCI. TH treatment as
well as the post-resuscitation syndrome have
been both associated with a pro-thrombotic
state [5]. In addition, altered absorption and
pharmacokinetics of different medications has
been reported with TH [1, 5].
The results of our meta-analysis did not show
a difference in clinical outcomes between
hypothermia patients receiving clopidogrel
versus newer agents. The lack of difference in
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stent thrombosis is in discordance with the
experimental findings of less efficacy of clopi-
dogrel compared with newer agents in TH [1, 2].
This comes in accordance with studies suggest-
ing a poor correlation between platelet testing
and clinical outcomes in patients receiving dual
antiplatelet therapy [2]. An increase in bleeding
events has been reported with TH [4], however;
we found no significant difference in major
bleeding events among clopidogrel and the
newer agents.
To the best of our knowledge, this is the first
conducted meta-analysis with the totality of
available data comparing clopidogrel to newer
antiplatelet agents in cases of TH after PCI. This
current analysis has some limitations. The small
sample size in our analysis might have not been
adequate to detect differences in our study
outcomes. However, there are only few avail-
able studies on the topic. Unfortunately, many
useful clinical data were not available for our
analysis, such as generation of drug eluting
stents used, shockable versus un-shockable
rhythms, laboratory and medications data.
While most of the available clinical studies in
this topic are observational studies, the only
included randomized study did not show a dif-
ference between clopidogrel and ticagrelor in
clinical outcomes [2]. The potential for
unmeasured bias exists due to the observational
nature of some of the included studies as well as
the diversity and complexity of patients expe-
riencing OHCA. Further randomized studies are
needed at a larger scale to better explore the
optimal dual antiplatelet treatment in cases of
TH.
CONCLUSIONS
This meta-analysis showed no difference
between clopidogrel and newer antiplatelet
agents in the incidence of stent thrombosis or
in-hospital mortality for PCI in cases of TH.
Further randomized studies are needed to
explore the optimal dual antiplatelet treatment
in TH.
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Scherstén F, Stenestrand U, James SK. Stent throm-
bosis in Sweden. Circ Cardiovasc Interv.
2009;2:401–8.
Cardiol Ther (2018) 7:185–189 189
